Nanna Therapeutics
David B. currently serves as the Head of Engineered Small Molecules for the US and UK at Astellas Pharma Inc, a position held since April 2024. Prior roles at Astellas include Division Head and President of Mitobridge and Nanna Therapeutics from April 2022 to April 2024, and Executive Director, Science and Strategy Advisor from March 2020 to January 2022. David's extensive tenure at Astellas began in April 2005, featuring several senior roles focusing on research management, project coordination, and medicinal chemistry leadership. David's earlier experience includes senior positions at Fujisawa Pharmaceutical Co. Ltd, where drug candidate discovery in infectious diseases was a primary focus. Educationally, David holds a B.Sc and Ph.D. in Organic Chemistry from Newcastle University, with further studies at Stanford University and the University of Wisconsin-Madison.
This person is not in any teams
This person is not in any offices
Nanna Therapeutics
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer.Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treatage-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies.Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.